Beyfortus (nirsevimab-alip), a long-acting monoclonal antibody, has been shown in a groundbreaking real-world trial to significantly reduce the incidence of respiratory syncytial virus (RSV) disease in newborns. The trial, which was the biggest of its kind in the US, showed that infants who had the medication had an 87% lower rate of RSV cases that required a trip to the doctor or hospital.
The trial, which took place during the 2023-2024 RSV season, also demonstrated a significant 98% decrease in hospitalizations due to RSV in babies who were taken Beyfortus compared to those who were not. These results offer compelling proof of Beyfortus’ ability to shield newborns from RSV, a prevalent and potentially dangerous respiratory infection.
Read More: Sanofi Accelerates Global Shipping of BEYFORTUS® Ahead of 2025–2026 RSV Season
In newborns and young children, RSV is a major cause of lower respiratory tract disease, which frequently results in pneumonia and bronchiolitis. For neonates, premature babies, and people with underlying medical issues, the virus can be especially harmful.
hese results support BEYFORTUS as a groundbreaking advancement in infant RSV disease prevention. With more than 40 real-world evidence studies to date, this latest study further strengthens the well-established body of data that shows that BEYFORTUS provides protection against RSV disease to help safeguard the health of all babies, regardless of whether they are born before or during the RSV season.
Ayman Chit
For the duration of a typical five-month season, Beyfortus, a single-dose injection, protects against RSV. A monoclonal antibody that targets the RSV F – protein, which is essential for the virus to infect human cells, provides passive immunity. It provides instant protection because, unlike a vaccine, it doesn’t wait for the baby’s immune system to react.
Both of the study’s co-primary endpoints were accomplished. While the second indicated that even in cases when an infant who got Beyfortus did get an RSV lung infection, they had fewer overall medical visits, the first showed an 87% reduction in RSV disease.
This most recent study expands on earlier research, such as a prospective, population-based surveillance study that indicated Beyfortus to be 93% effective in avoiding hospitalizations due to RSV and was reported in JAMA Pediatrics. The numerous studies’ consistent findings highlight this preventative treatment’s substantial public health benefits.
Beyfortus is authorized for use in children up to 24 months of age who are still at risk of developing severe RSV disease, as well as in newborns and infants born during or beginning their first RSV season. The encouraging outcomes of this extensive real-world trial are probably going to promote Beyfortus’s broad adoption as a vital weapon in the battle against RSV.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
